Key facts
- This page summarizes Eric Easom's Form 4 filing for AN2 Therapeutics, Inc. (ANTX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 31 Mar 2022, 20:15.
Eric Easom - 29 Mar 2022 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- ANTX
- Reported as of
- 29 Mar 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 31 Mar 2022, 20:15:20 UTC
- Prior SEC filing
- 24 Mar 2022
- Next SEC filing
- 16 May 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lucy Day, Attorney-in-Fact for Eric Easom
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eric Easom filed Form 4 for AN2 Therapeutics, Inc. (ANTX) on 31 Mar 2022.
Change
- Previous filing in this sequence was filed on 24 Mar 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ANTX
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +4,907
- Change %
- Price
- Shares after
- 4,907
- Date
- 29 Mar 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ANTX
transaction
Derivative
Series A Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -4,907
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 29 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,907
- Exercise price
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date.